Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of … T Knox, E Sahakian, D Banik, M Hadley, E Palmer, S Noonepalle, J Kim, ... Scientific reports 9 (1), 6136, 2019 | 151 | 2019 |
Targeting macrophages as a therapeutic option in coronavirus disease 2019 M Gracia-Hernandez, EM Sotomayor, A Villagra Frontiers in pharmacology 11, 577571, 2020 | 58 | 2020 |
HDAC6 plays a noncanonical role in the regulation of antitumor immune responses, dissemination, and invasiveness of breast cancer D Banik, S Noonepalle, M Hadley, E Palmer, M Gracia-Hernandez, ... Cancer research 80 (17), 3649-3662, 2020 | 46 | 2020 |
Enhancing therapeutic approaches for melanoma patients targeting epigenetic modifiers M Gracia-Hernandez, Z Munoz, A Villagra Cancers 13 (24), 6180, 2021 | 11 | 2021 |
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down … T Knox, E Sahakian, D Banik, M Hadley, E Palmer, S Noonepalle, J Kim, ... Scientific Reports 9 (1), 14824, 2019 | 7 | 2019 |
Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition SKR Noonepalle, S Grindrod, N Aghdam, X Li, M Gracia-Hernandez, ... Molecular Cancer Therapeutics 22 (12), 1376-1389, 2023 | 2 | 2023 |
Cytotoxicity of selenium trastuzumab and bevacizumab immunoconjugates against triple negative breast cancer cells S Khandelwal, L Gollahon, J Spallholz, M Boylan, ... Cancer Research 77 (13_Supplement), 4613-4613, 2017 | 2 | 2017 |
Targeting HDAC6 improves anti-CD47 immunotherapy M Gracia-Hernandez, AS Yende, N Gajendran, Z Alahmadi, X Li, Z Munoz, ... Journal of Experimental & Clinical Cancer Research 43 (1), 60, 2024 | 1 | 2024 |
Reprogramming macrophages with HDAC6 inhibitors for anti-cancer macrophage-based cell therapy S Noonepalle, M Gracia-Hernandez, C Zevallos-Delgado, N Aghdam, ... Survival 2 (5,000), 7,500-10,000, 2023 | 1 | 2023 |
Enhancing the effect of immunotherapy by inhibiting tumor promoting effect of HDAC6 D Banik, M Beaty, E Palmer, MDMG Hernandez, SK Noonepalle, ... Cancer Research 79 (13_Supplement), 2019-2019, 2019 | 1 | 2019 |
Reprogramming tumor microenvironment with intratumor macrophage adoptive cell therapy in melanoma SKR Noonepalle, N Gajendran, M Suresh, X Li, MD Hernandez, ... Cancer Research 84 (6_Supplement), 5247-5247, 2024 | | 2024 |
Characterizing the endogenous retroviral envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine MDM Maldonado, M Iida, MDMG Hernandez, L Le, RN Donahue, ... Cancer Research 84 (6_Supplement), 4092-4092, 2024 | | 2024 |
The advances in targeting CD47/SIRPα “do not eat me” axis and their ongoing challenges as an anticancer therapy M Gracia-Hernandez, M Suresh, A Villagra Oncotarget 15, 462, 2024 | | 2024 |
Stat-activated macrophages, compositions, and uses thereof A Villagra, S Noonepalle, MMG Hernandez US Patent App. 18/251,060, 2023 | | 2023 |
Compositions for and methods of treating cancer A Villagra, MMG Hernandez US Patent App. 18/297,565, 2023 | | 2023 |
Targeting the CD47/SIRPα “Do not eat me” phagocytic pathway in macrophages to improve anti-CD47 immune therapy N Gajendran, MG Hernandez, A Yende, Z Alahmadi, X Li, Z Munoz, ... Cancer Research 83 (7_Supplement), 666-666, 2023 | | 2023 |
Histone Deacetylase 6 Inhibitors as Adjuvants for Targeted and Immune Therapies in Melanoma MMG Hernandez The George Washington University, 2023 | | 2023 |
Stat-activated macrophages, compositions, and uses thereof MMGH Alejandro Villagra, Satish Noonepalle | | 2022 |
A novel treatment approach for melanoma by dually targeting MCT1 and MCT4 lactate transporters VS Sambad Sharma, Gregory Goreczny, Satish Kumar Noonepalle, Erica Palmer ... American Association for Cancer Research Annual Meeting 2021 81 (13), 1268, 2021 | | 2021 |
Abstract PO023: Immune-mediated tumor growth inhibition by selective HDAC6 inhibitor SP-2-225 S Grindrod, S Noonepalle, N Aghdam, A Velena, M Gracia-Hernandez, ... Cancer Immunology Research 9 (2_Supplement), PO023-PO023, 2021 | | 2021 |